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lipid content and duration of highly active
antiretroviral therapy exposure in patients
infected with human immunodeficiency
virus: a 3T cardiovascular magnetic
resonance feasibility study
Mariana Diaz-Zamudio1, Damini Dey2, Troy LaBounty4, Michael Nelson5,6, Zhaoyang Fan2, Lidia S. Szczepaniak2,5,
Bill Pei-Chin Hsieh1, Ronak Rajani1, Daniel Berman2, Debiao Li2, Rohan Dharmakumar2, W. David Hardy3
and Antonio Hernandez Conte7*
Abstract
Background: The aim of the current study was to examine whether the use of highly active antiretroviral therapy
(HAART) in patients with HIV is associated with changes in pericardial fat and myocardial lipid content measured by
cardiovascular magnetic resonance (CMR).
Methods: In this prospective case-control study, we compared 27 HIV seropositive (+) male subjects receiving
HAART to 22 control male subjects without HIV matched for age, ethnicity and body mass index. All participants
underwent CMR imaging for determination of pericardial fat [as volume at the level of the origin of the left main
coronary artery (LM) and at the right ventricular free wall] and magnetic resonance spectroscopy (MRS) for
evaluation of intramyocardial lipid content (% of fat to water in a single voxel at the interventricular septum). All
measurements were made by two experienced readers blinded to the clinical history of the study participants.
Two-sample t-test, Spearman’s correlation coefficient or Pearson’s correlation coefficient and multivariable logistic
regression were used for statistical analysis.
Results: Pericardial fat volume at the level of LM origin was higher in HIV (+) subjects (33.4 cm3 vs. 27.4 cm3, p = 0.03).
On multivariable analysis adjusted for age, Framingham risk score (FRS) and waist/hip ratio, pericardial fat remained
significantly associated to HIV-status (OR 1.09, p = 0.047). For both HIV (+) and HIV (-) subjects, pericardial fat volume
showed strong correlation with intramyocardial lipid content (r = 0.58, p < 0.0001) and FRS (r = 0.53, p = 0.0002). Among
HIV (+) subjects, pericardial fat was significantly higher in patients with lipo-accumulation (37 cm3 vs. 27.1 cm3, p = 0.03)
and showed significant correlation with duration of both HIV infection (r = 0.5, p = 0.01) and HAART (r = 0.46, p = 0.02).
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Conclusions: Pericardial fat content is increased in HIV (+) subjects on chronic HAART (>5 years), who demonstrate
HAART-related lipo-accumulation and prolonged HIV duration of infection. Further investigation is warranted to
determine whether increased pericardial fat is associated with higher cardiovascular risk leading to premature
cardiovascular events in this patient population.
Keywords: Human immunodeficiency virus, HIV, Cardiovascular magnetic resonance, Spectroscopy, Pericardial fat,
Highly active antiretroviral therapy, HAART, Intramyocardial lipid content
Background
Human immunodeficiency virus (HIV) infection persists
as a global pandemic despite significant advances in both
therapeutic and preventive interventions. For the past
5 years in the United States, the number of new persons
diagnosed with HIV infection has averaged 55,000 per
year [1, 2]. While the all-cause mortality directly related to
HIV infection has decreased substantially since the intro-
duction of highly active antiretroviral therapy (HAART),
an increasing number of HIV-infected persons are pre-
senting with newly diagnosed cardiovascular disease
(CVD). Morbidity and mortality related to HIV infection
remains high, with an increasing number of cardiovascular
events in this population [3, 4].
There is also evidence that HAART itself may contrib-
ute to cardiovascular risk, secondary to side-effects lead-
ing to lipodystrophy, hyperlipidemia, hyperglycemia and
potential direct cardiotoxicity [5–7]. Epicardial and thor-
acic fat have been associated with numerous endpoints of
CVD in non-HIV-infected populations (coronary artery
calcification, adverse cardiovascular events and myocardial
ischemia) [8–12]. Previous studies have found increased
epicardial fat in HIV-positive subjects and have raised
questions about its role in this population in elevating car-
diovascular risk [13, 14]. Recently, researchers have also
identified increased lipid content within the cardiac
muscle (cardiac steatosis) in HIV patients, and this has
also been promoted as a potential marker for cardiovascu-
lar risk in both HIV negative (-) and HIV seropositive (+)
individuals [15–17].
With this background, the primary aim of the current
study was to determine whether individuals with HIV on
chronic HAART have increased pericardial fat as assessed
by cardiovascular magnetic resonance (CMR) compared to
HIV-seronegative control subjects who have not been ex-
posed to HAART as either pre-exposure or post-exposure
prophylaxis. The secondary aim was to assess whether
such changes are related to traditional cardiovascular risk
factors and are associated with accompanying changes in
myocardial lipid content by CMR spectroscopy.
Methods
This study was reviewed and approved by the Cedars-Sinai
Institutional Review Board and all subjects provided
written informed consent prior to enrollment. A Certificate
of Confidentiality was obtained from the National Insti-
tutes of Health.
Subjects
Twenty-seven HIV (+) subjects on HAART were recruited
from the infectious disease clinic evaluated at the Cedars-
Sinai Medical Center in Los Angeles from April 2012
through to September 2013. Criteria for inclusion for pa-
tient subjects were: male gender, age of 35–55 years, HIV-
seropositive status confirmed by Western blot analysis,
and continuous HAART for at least 3 years. Exclusion cri-
teria for patient subjects included: known CVD, known
CVD risk factors such as diabetes, hypertension and fam-
ily history of premature CVD, history of Hepatitis C infec-
tion, intravenous drug use, prolonged interruptions of
HAART (greater than 3 months), history of a current
AIDS-defining illness and contraindications to undergoing
magnetic resonance imaging.
Controls
Twenty-two HIV-seronegative(-) men served as control
subjects; they were recruited from the same community.
HIV (-) control subjects were recruited via HIV (+) sub-
jects’ referral of friends, significant others, acquaintances
and persons in familiar social circles to approximate HIV
(+) subject characteristics. Inclusion criteria included:
HIV-seronegative status, age-matched (+/−3 years) of HIV
(+) subjects, race matched to HIV (+) subjects, sexual
orientation matched to HIV (+) subjects, social/lifestyle
medical history and anthropometric characteristics [i.e.
height, weight, body mass index (BMI)] were also all
matched to HIV (+) subjects. HIV seronegative status of
control subjects was confirmed with western blot HIV
analysis prior to imaging. Exclusion criteria for control
subjects included: known CVD, known CVD risk factors
such as diabetes, hypertension and family history of pre-
mature CVD, history of Hepatitis C infection, intravenous
drug use and any previous use of HIV-antiretroviral ther-
apy for pre- or post-exposure prophylaxis.
Clinical assessment
All subjects and controls completed a detailed medical
and social history questionnaire. For HIV (+) subjects,
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detailed information regarding HIV medical history, HIV
exposure history, sexual history and recreational drug
use was obtained from medical records. Comprehensive
HAART history was assessed by detailed review of medi-
cation records. Cumulative HAART exposure to each
antiretroviral agent and class of agent was calculated
based on months of exposure. Exposure to all antiretro-
viral agents implicated as “high risk” for CVD (i.e. abaca-
vir, amprenavir, didanosine, fosamprenavir, indinavir,
lopinavir) was also calculated.
A comprehensive physical exam was performed to as-
sess anthropometric variables. BMI was calculated from
measured height and weight. Waist/hip ratio was calcu-
lated from measured waist and hip circumference. The
presence of lipodystrophy (defined as the pathologic pres-
ence or absence of adipose tissue in various anatomic lo-
cations consistent with HAART-induced side-effects) was
assessed by an experienced infectious disease specialist. If
lipodystrophy was present, further physical evaluation was
performed to categorize (mild, moderate, severe) and to
differentiate anatomic presence of lipo-accumulation (ab-
domen, cervico-dorsal spine, anterior neck) and/or lipoa-
trophy (arms, buttocks, face, legs).
A fasting venous blood sample was obtained for meas-
urement of glucose, triglycerides, total cholesterol, HDL
cholesterol, LDL cholesterol, complete blood count
(hemoglobin, hematocrit, white blood cell count and
differential) and basic metabolic panel (electrolytes,
blood urea nitrogen and creatinine). Metabolic syn-
drome was defined as central obesity (waist circum-
ference > 94 cm) plus any two of the following: raised
triglycerides (> 150 mg/dL), reduced HDL cholesterol
(< 40 mg/dL), elevated blood pressure (> 130/85), elevated
fasting blood glucose (> 100 mg/dL) [18]. Framingham
cardiac risk factor scoring (FRS) was calculated according
to standard criteria, accounting for age, total cholesterol,
smoking history, HDL cholesterol and systolic blood pres-
sure [19]. Exercise levels were quantified based upon the
subject’s reporting of activity as 1) no exercise activity 2)
Mild = once per week 3) Moderate = 2–4 times per week
and 4) High = greater than 5 times per week.
Cardiovascular magnetic resonance protocol
All CMR and spectroscopy was performed using a 3.0-
Tesla whole body scanner (MAGNETOM Vario, Siemens
Medical, Erlangen, Germany). Imaging for pericardial fat
content used a Turbo FLASH sequence with a multi-slice
2D transverse acquisition and single-shot per slice was
performed. Thirteen slices in total, 6-mm thickness with
6-mm slice gap, FOV = 400 × 400 mm2, matrix = 144 ×
192, spatial resolution = 2.78 × 2.08 × 6 mm3, flip angle =
10, TR/TE = 3.2/1.27 ms, receiver bandwidth = 651 Hz/
pixel. Pericardial fat quantification was performed using
commercially-available ORS Visual Imaging Software
(Object Research Systems, Inc., 2013, Montreal, Canada),
in the following way: 1) as volume (cm3) in a 6 mm slab at
the level of the left main (LM) origin [20, 21]; 2) as volume
(cm3) in a 6 mm slab at the level of the right ventricular
(RV) free wall; and 3) as thickness (mm) of the pericardial
fat at RV free wall in the same slice [22–24]. Tracing of
the fat border was manually performed by two experienced
readers in cardiovascular imaging, blinded to HIV status.
We have previously published the intramyocardial
lipid content of the patients and controls studied in this
investigation [16]. We included the data here for refer-
ence purposes, and to test a completely separate hypoth-
esis (i.e. pericardial fat is related to intramyocardial lipid
content). To measure intramyocardial lipid content, a
spectroscopic volume of interest (single voxel, 6 cc) was
positioned over the intraventricular septum using end-
systolic cardiac cine images in 3 planes (short and long
axis), collected at end-expiration [16, 25]. During acqui-
sition of spectroscopic data, patients breathed freely,
with spectroscopic data acquisition triggered at end-
systole (via ECG gating) and end-expiration (via a re-
spiratory navigator). Spectroscopy data were processed
using commercially available software (NUTS, Acorn
NMR, Fremont, CA). The areas of resonances for water
and methylenes of fatty acids in triglycerides were quan-
tified by a line-fitting procedure accounting for signal
decay due to spin-spin relaxation. Triglyceride content
was expressed as a percentage of fat to water.
Statistical analysis
All continuous variables included in the analyses are
presented as mean ± SD. Variables with non-normal dis-
tributions are presented as median with range. Univari-
ate analyses were performed on continuous variables
using the two-sample t-test for normally distributed vari-
ables and the Mann-Whitney U test for non-normally
distributed data. The Spearman’s correlation coefficient
was used to assess the relationship between continuous
variables and ordinal data and the Pearson’s correlation
coefficient for non-continuous variables and interval
data. Multivariable logistic regression was used to deter-
mine the relationship of pericardial fat volume to HIV
status using FRS, waist and hip circumference as covari-
ates. Statistical significance for all analyses was set at the
5 % level. All statistical analyses were performed using
STATA (version 10, StataCorp LP, College Station, TX).
Results
Patients and controls
Detailed subject demographics and lipid measurements
are described in Table 1. HIV (+) subjects and HIV (-)
controls were similar with regard to age, sex, anthropo-
metric measurements and blood pressure. Resting heart
rate was significantly higher in HIV (+) subjects compared
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to control subjects. There were no significant differences
in blood glucose or lipid laboratory measurements be-
tween both groups. Seven of 27 (26 %) HIV (+) subjects
and 4 of 22 (20 %) controls were taking lipid-lowering
medications. Table 2 presents detailed HIV-related charac-
teristics of the HIV (+) subjects, as well as details of their
HAART exposure. All HIV (+) patients demonstrated
durable immunologic restoration and persistent viral sup-
pression for greater than 3 years and no AIDS-defining
diagnoses at the time of the study.
Pericardial fat reproducibility
Pearson correlation coefficients for interobserver agree-
ment were 0.98 (95 % CI 0.94–0.99, p < 0.0001) for peri-
cardial fat volume at the level of LM origin, 0.9 (95 % CI
0.72–0.97, p < 0.0001) for pericardial fat volume at the
level of RV free wall and 0.92 (95 % CI 0.77–0.97, p <
0.0001) for thickness of the pericardial fat at RV free wall.
Pericardial fat and intramyocardial lipid content in
HIV-positive and HIV-negative subjects
Pericardial fat volume at the level of the LM was signifi-
cantly higher in HIV (+) subjects compared to HIV (-)
controls (see Table 3). MR spectroscopy revealed a
three-fold elevation in intramyocardial lipid content in
HIV (+) subjects compared to controls (0.26 % vs. 0.85 %,
p = 0.005).
Pericardial fat predictors in all subjects
Pericardial fat volume at the level of LM origin showed
strong correlation with FRS (r = 0.53, p = 0.0002), BMI
Table 1 Subject characteristics
HIV (+) HIV (-) p
(n = 27) (n = 22)
Caucasian, % 100 100 ---
Age, years 48.1 ± 5.1 48.0 ± 4.7 0.93
Weight, kg 79.7 ± 11.2 78.0 ± 13.0 0.64
BMI, kg/m2 25 ± 4 24 ± 4 0.34
Hip circumference, cm 96.2 ± 7.0 96.8 ± 8.7 0.80
Waist circumference, cm 90.8 ± 11.6 86.2 ± 13.1 0.22
Waist/hip ratio 0.94 ± 0.09 0.89 ± 0.10 0.07
aFramingham Risk Score, % 3 (4) 3 (2) 0.88
Perform regular exercise, % 85 95 0.36
Median level of exercise 2 2 ---
Systolic blood pressure, mmHg 115 ± 15 122 ± 15 0.08
Diastolic blood pressure, mmHg 70 ± 9 67 ± 7 0.22
Resting heart rate, beats/min 76 ± 11 61 ± 10 <0.001
Total cholesterol, mg/dL 174 ± 33 180 ± 37 0.52
HDL Cholesterol, mg/dL 51 ± 13 54 ± 15 0.34
LDL Cholesterol, mg/dL 97 ± 26 91 ± 30 0.49
aTriglycerides, mg/dL 106 (69) 163 (106) 0.09
Glucose, mg/dL 90 ± 10 96 ± 14 0.08
Subjects self-reported whether they adhered to regular exercise (yes or no), with
the level of exercise ranked as: 0, none; 1, 1 × week; 2, 2–4 × week; 3, > 5 × week
BMI body mass index, LDL low-density lipoprotein, HDL high-density
lipoprotein
aData reported as mean ± standard deviation or median with interquartile range
Table 2 HIV (+) subject immunologic and HAART related
characteristics
Immunologic characteristic Mean ± SD Range
Prevalence
HIV History
Length of HIV diagnosis, months 196 ± 99 48–360
Previous history of AIDS-defining diagnosis, % 25 ---
Previous history of opportunistic infections, % 19 ---
Undetectable viral load > 3 years, % 100 ---
Compliance with HAART > 3 years, % 99 90–100
HAART-induced side effects
Metabolic syndrome, % 22 ---
Lipodystrophy, % 78 ---
Lipoatrophy, % 63 ---
Lipoaccumulation, % 67 ---
HAART Exposure
Cumulative HAART (any agent), months 157 ± 88 36–336
Cumulative exposure PI, months 91 ± 57 0–249
Cumulative exposure NRTI, months 163 ± 122 40–464
Cumulative exposure “high risk” PI, months 47 ± 33 0–103
Cumulative exposure NNRTI, monthsa 22 ± 63 0–156
Cumulative exposure INSTI, monthsa 5.5 ± 12.6 0–48
Cumulative exposure “high risk”
NRTI, monthsa
44.2 ± 73.9 0–273
Immunologic History
CD4+ cell counta 594 ± 326 242–2597
CD8+ cell counta 686 ± 356 312–1944
CD4+/CD8+ ratioa 78 ± 47 30–313
PI protease inhibitors, NRTI nucleoside reverse transcriptase inhibitors, NNRTI
non-nucleoside reverse transcriptase inhibitors, INSTI integrase strand transfer
inhibitors, High risk PI’s amprenavir, fosampenavir, indinavir, lopinavir, High risk
NRTI’s abacavir, didanosine
aData reported as mean + standard deviation or median with interquartile range
Table 3 Pericardial fat measures and myocardial lipid content in
HIV (+) subjects and HIV (-) controls
HIV (+) HIV (-) P value
n = 27 n = 22
Pericardial fat
Volume at LM origin, cm3 33.5 ± 12.5 27.5 ± 9.7 0.038
Volume at RV free wall, cm3 34.8 ± 12.4 33.4 ± 19 0.37
Thickness of pericardial fat at RV
free wall, mm
10.9 ± 4.9 10.8 ± 8.1 0.48
Myocardial lipid content, % 0.85 ± 1 0.26 ± 0.26 0.006
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(r = 0.71, p < 0.0001), waist circumference (r = 0.73, p <
0.0001), and waist/hip ratio (r = 0.7, p < 0.0001). No cor-
relation was observed between pericardial fat volume at
LM origin and family history (r = 0.06, p = 0.67), current
(r = 0.16, p = 0.27)/previous (r = 0.23, p = 0.11) smoking
or amount of exercise (r = 0.23, p = 0.1).
Pericardial fat volume at the level of RV free wall
showed a weaker correlation with FRS (r = 0.44, p =
0.002), and no correlation was observed between FRS
and thickness of pericardial fat at RV free wall (r = 0.29,
p = 0.05). Correlation coefficients between pericardial fat
measures and risk factors in all population, HIV (+) sub-
jects and HIV (-) controls is detailed in Table 4.
Pericardial fat and intramyocardial lipid content in all
subjects
Pericardial fat volume at the level of LM origin showed
strong correlation with intramyocardial lipid content
(r = 0.58, p < 0.0001, Fig. 1). Weaker correlation was
found with pericardial fat volume at the RV free wall (r =
0.5, p = 0.0004) and thickness of pericardial fat at RV free
wall (r = 0.44, p = 0.002).
Multivariable analysis
Multivariable analysis adjusted for age, Framingham Risk
Score (FRS) and waist/hip ratio, showed that only peri-
cardial fat at the level of the LM origin was significantly
associated to HIV-status (OR 1.09, 95 % confidence
interval 1 - 1.2, p = 0.047), over FRS and waist/hip ratio.
We also examined examined the relationship of pericar-
dial fat, intramyocardial lipid content and lipoaccumula-
tion with HIV-seropositivity. Intramyocardial lipid content
was associated with HIV-seropositivity (p = 0.034, OR7.83
995 % CI: 1.2–52.4) but the association was not significant
for either intramyocardial lipid content (p = 0.06) or peri-
cardial fat (p = 0.45) when considered together. This was
probably because the two measures are significantly corre-
lated (Spearman’s Rank correlation coefficient 0.58, p <
0.0001). Prevalence of lipo-accumulation was significantly
higher in HIV-seropositive subjects (18/23 or 78 %).
Pericardial fat predictors in HIV-positive subjects
Pericardial fat volume at the level of LM origin showed
significant correlation with time since HIV diagnosis
(r = 0.5, p = 0.01) and duration of HAART exposure
(r = 0.46, p = 0.02,). Pericardial fat volume at RV free wall
showed a weaker correlation with time since HIV diagno-
sis (r = 0.45, p = 0.02) and no correlation with duration of
HAART exposure (r = 0.38, p = 0.05). No correlation was
observed between fat thickness at RV free wall and time
since HIV diagnosis (r = 0.33, p = 0.1) or duration of
HAART exposure (r = 0.26, p = 0.2).
Regarding specific HAART medication class exposure
and pericardial fat volume at the level of LM origin, sig-
nificant correlation was found only with current use of
CCR5 receptor antagonists (r = 0.42, p = 0.03) and cumu-
lative exposure of CCR5 receptor antagonists in months
(r = 0.42, p = 0.03). Current NRTI use was negatively cor-
related (r = -0.42, p = 0.03).
Pericardial fat volume at the level of LM origin was
significantly higher in subjects with lipo-accumulation
(37 ± 13.3 cm3 vs. 27.1 ± 8.4 cm3, p = 0.03), but not in
subjects with generalized lipodystrophy (35.6 ± 13.1 cm3
vs. 26.8 ± 8 cm3, p = 0.07) or lipoatrophy (33.5 ± 12.8 cm3
vs. 33.4 ± 12.7 cm3, p = 0.48). Pericardial fat volume at RV
free wall was also significantly higher in patients with lipo-
accumulation (38.2 ± 13.3 cm3 vs. 28.6 ± 7.6 cm3, p =
0.03), whereas pericardial fat thickness at RV free wall
(11.5 ± 5.6 mm vs. 9.7 ± 3.6 mm, p = 0.19) was not signifi-
cantly different.
Discussion
HIV-related cardiovascular disease is an emerging con-
tributor to morbidity and mortality. Imaging biomarkers
such as pericardial or myocardial adiposity may serve as
markers of cardiovascular risk in this population. Com-
puted tomography is commonly used to quantify peri-
cardial fat deposition; however, computed tomography
remains limited by its need for ionizing radiation. CMR
provides a safe, reliable means of serial cardiac evalu-
ation without the hazards associated with ionizing radi-
ation. In our study, we utilized CMR to demonstrate
several important findings: first, that increased pericardial
Table 4 Pericardial fat volume and risk factors
All HIV (+) HIV (-)
r (p value) r (p value) r (p value)
BMI 0.71*** 0.58*** 0.79***
Waist circumference 0.73*** 0.65** 0.77***
Hip circumference 0.39** 0.24 (0.23) 0.63**
Waist/hip ratio 0.70 *** 0.71** 0.60**
Family history 0.06 (0.67) 0.3 (0.13) 0.33 (0.14)
Current smoking 0.16 (0.27) 0.01 (0.94) 0.29 (0.18)
Prior smoking 0.23 (0.11) 0.1 (0.62) 0.25 (0.26)
Level of exercise 0.23 (0.1) 0.08 (0.68) 0.36 (0.09)
Total cholesterol 0.24 (0.1) 0.19 (0.36) 0.35 (0.12)
LDL cholesterol 0.23 (0.12) 0.10 (0.61) 0.33 (0.15)
Triglycerides 0.39** 0.40 (0.051) 0.64**
Fasting glucose 0.10 (0.49) 0.04 (0.82) 0.05 (0.8)
Risk factors for metabolic syndrome 0.48** 0.34 (0.09) 0.58**
Framingham risk score 0.53** 0.41* 0.77***
Correlation Coefficients between pericardial fat volume at the level of LM
origin and risk factors in all population, HIV (+) subjects and HIV (-) controls
BMI body mass index, LDL low-density lipoprotein
*p < 0.05
**p < 0.01
***p < 0.0001
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fat at the level of the LM origin, measured quickly and re-
producibly from a standard CMR sequence, is significantly
higher in HIV (+) patients treated with HAART. Second,
this increase in pericardial fat is significantly associated
with increased intramyocardial lipid content (i.e. cardiac
steatosis). To our knowledge, this is the first report of this
correlation of pericardial fat with cardiac steatosis. Third,
we extend the existing literature [13, 14, 17] by showing
that each of these markers are also associated with HIV
history (i.e. years of infection), duration of HAART expos-
ure, as well as the clinical presence of lipo-accumulation
secondary to HAART. Remarkably, these results persist
despite rigorous screening for cardiovascular risk factors
in our HIV+ subjects, including family history of cardio-
vascular disease. That HAART exposure was found to be
related to derangements in fat metabolism, reinforces
the hypothesis that HAART itself contributes to car-
diac alterations.
The exact mechanism responsible for pericardial fat
deposition remains unclear. We found that HAART
exposure was strongly associated with pericardial fat de-
position, providing important mechanistic insight. In-
deed, HAART is known to cause both lipodystrophy and
hyperlipidemia [5–7] and in the present investigation,
was associated with lipo-accumulation. Triglyceride infil-
tration into the myocardium has previously been associ-
ated with derangements in both diastolic relaxation and
systolic contractility in both rodents [26–29] and humans
[30, 31] One explanation for this observation is that ec-
topic fat accumulation contributes to the generation of
lipotoxic intermediates, such as ceramide, which can trig-
ger myocellular apoptosis [32]. Lipid vacuole infiltration
can also dissemble the myocardial contractile apparatus,
which could independently lead to contractile dysfunction
[8, 33]. Thus, while our data cannot prove causality, we
hypothesize that chronic exposure to HAART produces a
metabolic-type derangement (clinically or non-clinically
evident) leading to myocardial and pericardial fat accumu-
lation. Taken together, we speculate that disturbances in
the metabolic milieu, secondary to HAART exposure,
leads to ectopic fat accumulation in HIV+ patients.
Clinical relevance
Identification of multiple risk factors in the development
of pericardial fat or myocardial triglyceride accumulation
in HIV+ patients on HAART is paramount in develop-
ing clinical algorithms for appropriate cardiac screening
and risk reduction implementation. Factors such as dur-
ation of HAART exposure, specific exposure to “cardio-
toxic” antiretroviral agents, or overall duration of HIV
infection may guide the clinician in screening maneu-
vers. Chronologic age alone cannot be the sole criteria
for routine cardiovascular screening and assessment, as
many individuals become infected with HIV at a rela-
tively young age and have been on HAART for over a
decade by the time they reach their early 30’s or 40’s.
Thus, the concept of chronologic age as a cardiovascular
screening indictor may be irrelevant, especially in youn-
ger HIV+ patients. As such, defining “HIV-infection-
age” and “HAART-exposure” may be more informative
to the clinician for CVD screening and assessment.
Ectopic fat deposition is emerging as an independent
marker of cardiovascular risk in HIV-infected patients as
demonstrated via computed tomography [34, 35]. In a
study by Guaraldi et al. [14], epicardial adipose tissue was
strongly associated with coronary artery calcium (an estab-
lished marker of atherosclerosis) in patients with HIV in-
fection on HAART. In our study, we show that pericardial
fat deposition is related to HIV history, duration of
HAART exposure, as well as the clinical presence of lipo-
accumulation secondary to HAART. While these two fat
depots are not entirely the same, both have been impli-
cated in the development of coronary artery disease [36].
Further investigation is therefore warranted to determine
Fig. 1 Pericardial fat volume quantification at level of the LM origin. On the right, 49 year old HIV (+) subject with BMI 24 kg/m2 and 27 years on
HAART, quantification on CMR revealed a high pericardial fat volume and myocardial lipid content. On the left, 49 year old HIV (-) volunteer with
BMI 29.5 kg/m2, quantification showed low pericardial fat volume and myocardial lipid content
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whether pericardial fat content, measured by routine CMR,
will be equally predictive for cardiovascular risk in HIV.
Although our study did not find specific protease in-
hibitors or nucleoside reverse transcriptase inhibitors
(which are known to have cardiotoxic effects) to be
more predictive of cardiac steatosis or pericardial fat ac-
cumulation, compared to other medications, the present
investigation was not specifically powered to detect such
differences. However caution must continue to be exer-
cised when these medications are prescribed, and during
routine CVD risk stratification.
Routine clinical qualitative screening for external lipo-
dystrophy may serve as a useful screening tool for fur-
ther CVD screening in this patient population. Indeed,
this study utilized a straightforward method of evaluat-
ing lipodystrophy that can be performed by a general or
subspecialist physician during a regular outpatient office
consultation. Importantly, traditional indicators for CVD
such as body mass index were not found to be associ-
ated with increased cardiac steatosis in HIV-infected pa-
tients on HAART, whereas waist/hip circumference ratio
and lipodystrophy screening were found to be highly
correlated with cardiac alterations.
Limitations
There were several limitations to this study. First, our
study population was small, however, both the patient and
control groups were highly homogeneous with regard to
multiple demographic parameters. Our selection process
of HIV (-) control subjects closely approximated the HIV
(+) subjects, therefore, the two study groups were very
similar aside from HIV status and use of HAART. Second,
our measurements provide information about pericardial
fat and not exclusively epicardial fat, which has been pro-
posed as the best marker for cardiovascular risk among
thoracic fat deposits [8, 12]. Furthermore, our measure-
ments of pericardial fat are obtained from a single slab in
order to propose a practical fast approach to pericardial
fat quantification, nevertheless a full volumetric assess-
ment is more desirable and could be introduced in the fu-
ture. Third, this was a cross-sectional study of HIV (+)
patients on multiple HAART regimens, therefore, associa-
tions between specific classes of HAART and pericardial
fat and intramyocardial lipid content were limited due to
small groups of patients on particular medication regi-
mens. Larger cohorts of HIV (+) patients on specific
HAART regimens are necessary to determine medication
class-induced risk profiles. This study did not include a
group of HIV-infected patients without history of HAART
exposure, thus preventing us from completely partitioning
the independent role of HIV infection (without HAART)
per se. In the United States, HAART is immediately im-
plemented once the patient is able to make a decision to
accept the risks and benefits of therapy, therefore, it would
be extremely difficult to recruit a subset of HIV+ subjects
without history of HAART. Finally, this study was limited
to male subjects due to its sample size and significant re-
ported differences in patient characteristics by gender
among patients with HIV. As a result, these findings may
not be generalizable to women, and future research in
women is warranted. Studies in non-HIV-infected individ-
uals have implicated pericardial fat accumulation with in-
creasing cardiovascular risk and events [10–12]. Further
studies are therefore warranted to investigate the relation-
ship between pericardial fat accumulation and cardiovas-
cular events in HIV-infected subjects.
Conclusions
Our study show that pericardial fat, measured at the origin
of LM, can be done both quickly and reproducibly and is
highly correlated with intramyocardial lipid content, years
of HIV infection, duration of HAART exposure and the
clinical presence of lipo-accumulation. Pericardial fat by
CMR therefore represents a viable biomarker for assessing
cardiovascular risk in this population.
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